Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/52906
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3392]
Metadata
Show full item record
EFFECTIVENESS OF CORONAVAC AMONG HEALTHCARE WORKERS IN THE SETTING OF HIGH SARS-COV-2 GAMMA VARIANT TRANSMISSION IN MANAUS, BRAZIL: A TEST-NEGATIVE CASE-CONTROL STUDY
Author
Hitchings, Matt D. T.
Ranzani, Otavio T.
Torres, Mario Sergio Scaramuzzini
Oliveira, Silvano Barbosa de
Almiron, Maria
Said, Rodrigo
Borg, Ryan
Schulz, Wade L.
Oliveira, Roberto Dias de
Silva, Patricia Vieira da
Castro, Daniel Barros de
Sampaio, Vanderson de Souza
Albuquerque, Bernardino Cláudio de
Ramos, Tatyana Costa Amorim
Fraxe, Shadia Hussami Hauache
Costa, Cristiano Fernandes da
Naveca, Felipe Gomes
Siqueira, Andre M.
Araújo, Wildo Navegantes de
Andrews, Jason R.
Cummings, Derek A. T.
Ko, Albert I.
Croda, Julio
Ranzani, Otavio T.
Torres, Mario Sergio Scaramuzzini
Oliveira, Silvano Barbosa de
Almiron, Maria
Said, Rodrigo
Borg, Ryan
Schulz, Wade L.
Oliveira, Roberto Dias de
Silva, Patricia Vieira da
Castro, Daniel Barros de
Sampaio, Vanderson de Souza
Albuquerque, Bernardino Cláudio de
Ramos, Tatyana Costa Amorim
Fraxe, Shadia Hussami Hauache
Costa, Cristiano Fernandes da
Naveca, Felipe Gomes
Siqueira, Andre M.
Araújo, Wildo Navegantes de
Andrews, Jason R.
Cummings, Derek A. T.
Ko, Albert I.
Croda, Julio
Affilliation
University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute. Gainesville, FL, USA.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clinicas HCFMUSP. Heart Institute (InCor). Pulmonary Division. São Paulo, SP, Brazil / ISGlobal. Barcelona Institute for Global Health. Barcelona, Spain.
Municipal Health Secretary of Manaus. Manaus, AM, Brazil.
Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília. Brasília, DF, Brazil.
Pan American Health Organization. Brasília, DF, Brazil.
Pan American Health Organization. Brasília, DF, Brazil.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Yale-New Haven Hospital. Center for Outcomes Research and Evaluation. New Haven, CT, USA / Yale University School of Medicine. Department of Laboratory Medicine. New Haven, CT, USA.
State University of Mato Grosso do Sul - UEMS. Dourados, MS, Brazil.
Universidade Federal de Mato Grosso do Sul - UFMS. Campo Grande, MS, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Municipal Health Secretary of Manaus. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Manaus, AM, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília. Brasília, DF, Brazil / National Institute for Science and Technology for Health Technology Assessment. Porto Alegre, RS, Brazil.
Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, USA.
University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute. Gainesville, FL, USA.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Universidade Federal de Mato Grosso do Sul - UFMS. Campo Grande, MS, Brazil.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clinicas HCFMUSP. Heart Institute (InCor). Pulmonary Division. São Paulo, SP, Brazil / ISGlobal. Barcelona Institute for Global Health. Barcelona, Spain.
Municipal Health Secretary of Manaus. Manaus, AM, Brazil.
Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília. Brasília, DF, Brazil.
Pan American Health Organization. Brasília, DF, Brazil.
Pan American Health Organization. Brasília, DF, Brazil.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Yale-New Haven Hospital. Center for Outcomes Research and Evaluation. New Haven, CT, USA / Yale University School of Medicine. Department of Laboratory Medicine. New Haven, CT, USA.
State University of Mato Grosso do Sul - UEMS. Dourados, MS, Brazil.
Universidade Federal de Mato Grosso do Sul - UFMS. Campo Grande, MS, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Fundação de Vigilância em Saúde do Estado do Amazonas. Manaus, AM, Brazil.
Municipal Health Secretary of Manaus. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Manaus, AM, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília. Brasília, DF, Brazil / National Institute for Science and Technology for Health Technology Assessment. Porto Alegre, RS, Brazil.
Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, USA.
University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute. Gainesville, FL, USA.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Universidade Federal de Mato Grosso do Sul - UFMS. Campo Grande, MS, Brazil.
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, Gamma, emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus disease (COVID-19), and has spread throughout Brazil. The effectiveness of vaccines in settings with widespread Gamma variant transmission has not been reported.
Methods: We performed a matched test-negative case-control study to estimate the effectiveness of an inactivated vaccine, CoronaVac, in healthcare workers (HCWs) in Manaus, where the Gamma variant accounted for 86% of genotyped SARS-CoV-2 samples at the peak of its epidemic. We performed an early analysis of effectiveness following administration of at least one vaccine dose and an analysis of effectiveness of the two-dose schedule. The primary outcome was symptomatic SARS-CoV-2 infection.
Findings: For the early at-least-one-dose and two-dose analyses the study population was, respectively, 53,176 and 53,153 HCWs residing in Manaus and aged 18 years or older, with complete information on age, residence, and vaccination status. Among 53,153 HCWs eligible for the two-dose analysis, 47,170 (89%) received at least one dose of CoronaVac and 2,656 individuals (5%) underwent RT-PCR testing from 19 January, 2021 to 13 April, 2021. Of 3,195 RT-PCR tests, 885 (28%) were positive. 393 and 418 case-control pairs were selected for the early and two-dose analyses, respectively, matched on calendar time, age, and neighbourhood. Among those who had received both vaccine doses before the RT-PCR sample collection date, the average time from second dose to sample collection date was 14 days (IQR 7-24). In the early analysis, vaccination with at least one dose was associated with a 0.50-fold reduction (adjusted vaccine effectiveness (VE), 49.6%, 95% CI 11.3 to 71.4) in the odds of symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the first dose. However, we estimated low effectiveness (adjusted VE 36.8%, 95% CI -54.9 to 74.2) of the two-dose schedule against symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the second dose. A finding that vaccinated individuals were much more likely to be infected than unvaccinated individuals in the period 0-13 days after first dose (aOR 2.11, 95% CI 1.36-3.27) suggests that unmeasured confounding led to downward bias in the vaccine effectiveness estimate.
Interpretation: Evidence from this test-negative study of the effectiveness of CoronaVac was mixed, and likely affected by bias in this setting. Administration of at least one vaccine dose showed effectiveness against symptomatic SARS-CoV-2 infection in the setting of epidemic Gamma variant transmission. However, the low estimated effectiveness of the two-dose schedule underscores the need to maintain non-pharmaceutical interventions while vaccination campaigns with CoronaVac are being implemented.
Share